Tivozanib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), DMC (Denmark) and NICE (England), among others, recommended or restricted tivozanib, while NYE METODER (Norway) did not recommend it.
Where tivozanib met resistance it was usually narrowed rather than refused: 3 of 6 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
The record spans 2.7 years, opening at AWMSG (Wales) on 13 Jul 2017 and running to 25 Mar 2020.
No assessment is on file from HAS (France), PBAC (Australia), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
Nothing has been added since 2020; on this evidence the file is dormant.
3 distinct indication wordings are recorded for tivozanib by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess tivozanib, on 13 Jul 2017; AOTMIT (Poland) did not open a file until 25 Mar 2020 — a moderate spread of 2.7 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 7 dated records fall in 2018 alone.
Restriction is doing real work here: 3 of 6 decisive outcomes narrowed tivozanib to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), NICE (England) and SMC (Scotland).
8 of the 18 agencies in this archive hold a record for tivozanib.
The full ledger for tivozanib reads 3 restricted, 2 recommended, 1 not recommended and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 25 Mar 2020 | programu lekowego „Leczenie raka nerki (ICD- 10: C.64) | recommended conditionally | source |
| NYE METODER (Norway) | 28 Apr 2019 | Førstelinjebehandling av lokalavansert eller metastatisk nyrecellekarsinom | not introduced | source |
| TLV (Sweden) | 1 Oct 2018 | Fotivda ingår i högkostnadsskyddet | general subsidy | source |
| SMC (Scotland) | 9 Jul 2018 | For the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are vascular endothelial growth factor receptor (VEGFR)… | accepted (restricted) | source |
| G-BA (Germany) | 19 Apr 2018 | Fotivda — benefit assessment §35a | added benefit: not proven | source |
3 further decisions for tivozanib, across 3 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- cabozantinib — divergent outcome (restricted vs not recommended) on a shared indication
- sunitinib — divergent outcome (restricted vs recommended) on a shared indication
- pazopanib — divergent outcome (restricted vs recommended) on a shared indication
- lenvatinib — divergent outcome (restricted vs recommended) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
Coverage: 8 decisions for tivozanib from 8 agencies, 2017 to 2020. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.